# A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

> **NCT04902027** · PHASE1 · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 45 (actual)

## Conditions studied

- Recurrent Head and Neck Cancer
- Metastatic Head and Neck Cancer

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

## Key facts

- **NCT ID:** NCT04902027
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2023-10-23
- **Final completion:** 2023-10-23
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04902027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04902027, "A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04902027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*